		patient data on this form if the head enter ID, and visit number.	er does not	contain <i>pre</i>	eprinted HALT			
M	Participant ID:	haltid Clinical Center:	clinic Date	e of Report	ay dyd year dyy			
A	visit:		month dvm day dvd year dvy Form was not completed misfrm					
	PARTICIPANT NEXT TO	LAST VISIT QUESTIONNAIRI	E (options)	Form # 130			
De	ar Participant,							
During your visit today, we ask that you provide us with the answers to the questions below. This information will assist the HALT-PKD team to safely transition your clinical care back to your local physician when the study ends. Your study coordinator will assist you to complete this questionnaire.								
1)	During today's visit, did you comp #2-"Contact Information Form"? form		1 🗌 Yes	0 🗌 No				
2)	Do you have a PCP or nephrologis team to transition your care to in s		1 🗌 Yes	0 🗌 No	3 Unsure			
	2a) If no or unsure, do you have accenter or clinic? Please provide the coordinator. clinicAccess		1 🗌 Yes	0 🗌 No	3 Unsure			
3)	When the study comes to an end, insurance, Medicaid or Medicare c		1 🗌 Yes	0 🗌 No	3 Unsure			
	3a) If no or unsure, do you plan to coverage? If so, please start the ap two weeks. applyCoverage		1 🗌 Yes	0 🗌 No	3 Unsure			
4)	Once the study results are release depending on your response below physician you identified on Form # information gathered over the cour provide your lab results (kidney funct kidney volume on MRI-Study A only) blood pressure measurement, and you (either telmisartan or placebo).	w, will send you, and the #2, a letter containing your study rse of the study. This letter will ion-eGFR), radiology results (total, current stage of kidney disease,	1 participant notified of planned release of study information. ptnotified					
	4a) Do you want to receive your st receiveResults	udy results information?	1 🗌 Yes	0 🗌 No				
	4b) Do you give the HALT PKD stud study results with your local physic		1 Yes	0	3 N/A no provider identified)			
5)	Do you want to be told what study you were assigned to during your		1 🗌 Yes	0 🗌 No				
5a) Do you give the HALT PKD study permission to share your treatment allocation (telmisartan or placebo) with your local physician? shareTreatment			1 🗌 Yes	0	3 N/A no provider identified)			
6)	Please identify the physician or de receive the final study letter. provide		1 PCP/PA/CRNP (Form #2 item 10)					
**Please contact the study staff if you change your local physician and provide updated contact information.			OR 2 Nephrologist (Form #2 item 11)					
			, ,	(declined release	ase of results)			

notificationMethod

information.

7) How would you like us to send the final study letter to you?

**Please contact the study staff if you relocate and provide updated contact

1 email account

2 certified mail

identify primary email account on Form 2 only

3 N/A (declined release of results)

	Attention - DO NOT enter patient data on this form if the header does not contain <i>preprinted</i> HALT PKD ID number, clinical center ID, and visit number.						
Participant ID: haltid Clir		clinic Date of Repo	rt: / /				
visit:			day dvd year dvy completed misfrm				
PARTICIPANT NEXT TO LAST VISIT	QUESTIONNAIRE		Form # 130				
COMMENTS: comments	40_0110111111111	- (0 00000)					
COMMENTS. Comments							
**PARTICIPANT NAME:							
**PARTICIPANT SIGNATURE:							
**These form fields are excluded from entry into the HALT-PKD do	atabase to protect confiden	tiality.					
COORDINATOR NAME:							
***************************************			*******				
HALT PKD staff member completing this form:	cmidnum	Date:	Day cdd Year cdy				
Data Entry Status: Please check to indicate that t			Day coo real coy				
Data Littiy Status. Flease Check to indicate that t	ine above initititation	ו וומס טכטוו טוונטוטט					
Primary Entered by:		Date:/	dod Day day Yeer				
deidnum		aem Wonth a	ueu ⊔ay aey rear				